Zobrazeno 1 - 10
of 228
pro vyhledávání: '"Michael, Schiff"'
Autor:
Vibeke Strand, Michael Schiff, Namita Tundia, Alan Friedman, Sebastian Meerwein, Aileen Pangan, Arijit Ganguli, Mahesh Fuldeore, Yan Song, Janet Pope
Publikováno v:
Arthritis Research & Therapy, Vol 21, Iss 1, Pp 1-10 (2019)
Abstract Background Patient-reported outcomes (PROs) are important when evaluating treatment benefits in rheumatoid arthritis (RA). We compared upadacitinib, an oral, selective JAK-1 inhibitor, with placebo to assess clinically meaningful improvement
Externí odkaz:
https://doaj.org/article/bd8fbaf30aae45f5842abd209051f909
Autor:
Vibeke Strand, Janet Pope, Namita Tundia, Alan Friedman, Heidi S. Camp, Aileen Pangan, Arijit Ganguli, Mahesh Fuldeore, Debbie Goldschmidt, Michael Schiff
Publikováno v:
Arthritis Research & Therapy, Vol 21, Iss 1, Pp 1-11 (2019)
Abstract Background To evaluate the effect of upadacitinib on patient-reported outcomes (PROs) in patients with RA who had an inadequate response to csDMARDs. Methods Patients in SELECT-NEXT, a randomised controlled trial, were on a background of csD
Externí odkaz:
https://doaj.org/article/3883782900f14f38bac33e7572de4663
Autor:
Roy Fleischmann, Michael Weinblatt, Harris Ahmad, Michael A. Maldonado, Evo Alemao, June Ye, Michael Schiff
Publikováno v:
Rheumatology and Therapy, Vol 6, Iss 4, Pp 559-571 (2019)
Abstract Introduction Patients with rheumatoid arthritis (RA) with poor prognostic factors, such as seropositivity for anti-citrullinated protein antibodies and early erosions, may benefit from early intensive treatment. However, information to guide
Externí odkaz:
https://doaj.org/article/bacb69c25d2542d1835b46507de62903
Autor:
Michael Schiff, Tsutomu Takeuchi, Roy Fleischmann, Carol L. Gaich, Amy M. DeLozier, Douglas Schlichting, Wen-Ling Kuo, Ji-Eon Won, Tara Carmack, Terence Rooney, Patrick Durez, Saeed Shaikh, Rodolfo Pardo Hidalgo, Ronald van Vollenhoven, Cristiano A. F. Zerbini
Publikováno v:
Arthritis Research & Therapy, Vol 19, Iss 1, Pp 1-10 (2017)
Abstract Background This study evaluates patient-reported outcomes (PROs) in a double-blind, phase III study of baricitinib as monotherapy or combined with methotrexate (MTX) in patients with active rheumatoid arthritis (RA) with no or minimal prior
Externí odkaz:
https://doaj.org/article/e7c12c27d7be4b6986dc14312f729acc
Autor:
Vibeke Strand, Janet Pope, Namita Tundia, Alan Friedman, Heidi S. Camp, Aileen Pangan, Arijit Ganguli, Mahesh Fuldeore, Debbie Goldschmidt, Michael Schiff
Publikováno v:
Arthritis Research & Therapy, Vol 22, Iss 1, Pp 1-2 (2020)
An amendment to this paper has been published and can be accessed via the original article.
Externí odkaz:
https://doaj.org/article/ac9cd828bf7c48e680672ea4113864bd
Autor:
Désirée van der Heijde, Yoshiya Tanaka, Paul Emery, Li Xie, Michael Schiff, Gabriella Meszaros, Taeko Ishii, Marta Casillas, Robert A Ortmann
Publikováno v:
RMD Open, Vol 5, Iss 1 (2019)
Objectives To evaluate radiographic progression of structural joint damage over 2 years in patients with rheumatoid arthritis from baricitinib clinical trials who were disease-modifying antirheumatic drug (DMARD)–naïve or had an inadequate respons
Externí odkaz:
https://doaj.org/article/be6b2b26b8de45dd8bafd2d67de4083f
Autor:
Omar Jabado, Michael A. Maldonado, Michael Schiff, Michael E. Weinblatt, Roy Fleischmann, William H. Robinson, Aiqing He, Vishal Patel, Alex Greenfield, Jasmine Saini, David Galbraith, Sean E. Connolly
Publikováno v:
Rheumatology and Therapy. 9:391-409
The biologics abatacept and adalimumab have different mechanisms of action (MoAs). We analyzed data from patients with rheumatoid arthritis treated in AMPLE (NCT00929864) to explore the pharmacodynamic effects of abatacept or adalimumab on anti-citru
Autor:
Tessa M Burch-Smith, Michael Schiff, Jeffrey L Caplan, Jeffrey Tsao, Kirk Czymmek, Savithramma P Dinesh-Kumar
Publikováno v:
PLoS Biology, Vol 14, Iss 1, p e1002374 (2016)
[This corrects the article DOI: 10.1371/journal.pbio.0050068.].
Externí odkaz:
https://doaj.org/article/cba251689c584b27a3d4a967e7913464
Autor:
Namita Tundia, Arijit Ganguli, Aileen L. Pangan, Michael Schiff, Mahesh Fuldeore, Janet E. Pope, Sebastian Meerwein, Yan Song, Vibeke Strand, Alan Friedman
Publikováno v:
Arthritis Research & Therapy, Vol 21, Iss 1, Pp 1-10 (2019)
Arthritis Research & Therapy
Arthritis Research & Therapy
Background Patient-reported outcomes (PROs) are important when evaluating treatment benefits in rheumatoid arthritis (RA). We compared upadacitinib, an oral, selective JAK-1 inhibitor, with placebo to assess clinically meaningful improvements in PROs
Autor:
Michael Schiff, Wolfgang Kruis
Publikováno v:
Digestion. 101:500-505
Background/Aims: Ischemic colitis (IC) is most common in the elderly and patients with multiple comorbidities. It carries significant mortality. As yet no evidence-based therapeutic management exists. Aim of the study was to test therapeutic efficacy